Drug intelligence / Profile preview

gallium-68 PSMA-R2

Development stage: Phase 2
Lead developer: Advanced Accelerator Applications
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Gallium-68 PSMA-R2 is a radiopharmaceutical diagnostic agent composed of a prostate-specific membrane antigen (PSMA)-targeting ligand (PSMA-R2) conjugated to the positron-emitting radioisotope gallium-68. It is designed for use in PET/CT imaging to detect and localize PSMA-expressing prostate cancer lesions, including metastatic and recurrent disease. The drug binds specifically to PSMA, which is highly expressed on prostate cancer cells, allowing targeted delivery of the radioactive tracer for high-sensitivity imaging. Gallium‑68 PSMA‑R2 has demonstrated favorable safety and tolerability profiles in clinical trials, with rapid clearance from non-target tissues and low radiation exposure to salivary and lacrimal glands compared with other agents. Its primary indication is the diagnosis of prostate cancer, particularly in patients with biochemical recurrence or metastatic castration-resistant disease[1][3][4][5].

Other names: gallium Ga 68-PSMA-R2[68Ga]Ga-PSMA-R2

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on gallium-68 PSMA-R2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium-68 PSMA-R2.

Explore the full profile